Intra-Cellular Q1 2022 Earnings Report
Key Takeaways
Intra-Cellular Therapies reported a total revenue of $35 million for Q1 2022, a 120% increase compared to Q1 2021. CAPLYTA net product revenues were $34.8 million, representing a 123% increase year-over-year. The company's net loss was $72.1 million, and cash, cash equivalents, and investment securities totaled $773.2 million.
Total revenues for Q1 2022 were $35.0 million, a 120% increase compared to $15.9 million in Q1 2021.
CAPLYTA net product revenues were $34.8 million for Q1 2022, a 123% increase compared to $15.6 million for the same period in 2021.
CAPLYTA new and total prescriptions increased 63% and 45%, respectively, versus the fourth quarter 2021.
Net loss for the quarter ended March 31, 2022, was $72.1 million, compared to a net loss of $52.7 million for the quarter ended March 31, 2021.
Intra-Cellular
Intra-Cellular
Forward Guidance
Intra-Cellular Therapies anticipates continued strong growth of CAPLYTA and is advancing its pipeline, including lumateperone programs in MDD and mixed features.